Trials / Not Yet Recruiting
Not Yet RecruitingNCT07499232
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 530 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Guselkumab will be administered. |
| DRUG | Risankizumab | Risankizumab will be administered. |
Timeline
- Start date
- 2026-04-20
- Primary completion
- 2028-11-15
- Completion
- 2030-12-11
- First posted
- 2026-03-30
- Last updated
- 2026-04-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07499232. Inclusion in this directory is not an endorsement.